Hoersholm;23 October 2013 - Medical Prognosis Institute A/S (MPI) has been granted 3.5million DKK from The Danish Market Development Fund for further development and clinical testing of MPI's Lung Prognosticator. The aim of the test is to identify lung cancer patients, who with high likelihood will have relapse after surgery allowing adjuvant therapy to be considered. It is expected that early treatment of this subgroup of patients will reduce the mortality.
Help employers find you! Check out all the jobs and post your resume.
